Venous Thromboembolism Global Market Report 2025

Description

Venous thromboembolism (VTE) is a medical condition marked by the development of blood clots within the veins, carrying the potential for serious or life-threatening complications. Common indicators of VTE encompass symptoms like leg pain and swelling, rapid breathing, chest discomfort, and more. Diverse treatment methods, including anticoagulant medications, medical devices, and thrombolytic therapy, are employed in managing VTE.

The primary categories of venous thromboembolism consist of deep vein thrombosis, pulmonary embolism, and other related conditions. Deep vein thrombosis (DVT) represents a medical condition characterized by the development of blood clots within the deep veins of the body. Treatment options encompass the use of anticoagulant medications, mechanical devices, thrombolytic therapy, and various other interventions. These treatments cater to diverse end-users, including hospitals, homecare settings, specialty centers, and other relevant healthcare facilities.

The venous thromboembolism market research report is one of a series of new reports from The Business Research Company that provides venous thromboembolism market statistics, including venous thromboembolism industry global market size, regional shares, competitors with a venous thromboembolism market share, detailed venous thromboembolism market segments, market trends and opportunities and any further data you may need to thrive in the venous thromboembolism industry. This venous thromboembolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The venous thromboembolism market size has grown steadily in recent years. It will grow from $2.44 billion in 2024 to $2.55 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to aging population, advancements in anticoagulants, reimbursement policies, increasing investments.

The venous thromboembolism market size is expected to see steady growth in the next few years. It will grow to $3.02 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to global healthcare access, genetic risk assessment, telemedicine and remote monitoring, patient education and support. Major trends in the forecast period include extended thromboprophylaxis, novel oral anticoagulants, personalized treatment plans, advanced diagnostic imaging.

The expansion of healthcare infrastructure is expected to drive the growth of the venous thromboembolism (VTE) market. Healthcare infrastructure refers to the systems, institutions, policies, and resources that enable the delivery of medical care, including prevention, treatment, and rehabilitation services. The growing healthcare industry supports the implementation of VTE prevention protocols and the development of related treatments. For example, in May 2023, the American Health Care Association reported an increase in the number of hospitals in the U.S., rising from 6,093 in 2022 to 6,129 in 2023. Similarly, the Office for National Statistics in the UK reported a 5.6% increase in healthcare expenditure, which reached £292 billion in 2023. Additionally, long-term health and social care expenditures rose by 2.8% in real terms in 2022. As healthcare systems expand, they will increasingly focus on VTE prevention, thus boosting the market for related products and services.

The growth of the venous thromboembolism market is further bolstered by the escalating number of orthopedic procedures. Orthopedic procedures encompass various surgical interventions used to address conditions affecting the spine, joints, and skeletal deformities. Procedures like total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery (HFS) are associated with a heightened risk of VTE, leading to an increased adoption of compression devices for DVT prophylaxis. Compression devices serve to prevent the formation of blood clots in the deep veins of the legs, mitigating the risk of venous thromboembolism (VTE). For instance, research published by the National Library of Medicine in February 2023 indicates that THA and TKA procedures are projected to rise significantly, with 1,222,988 and 719,364 procedures, respectively, anticipated by 2040. Moreover, TKAs are estimated to reach 2,917,959 by 2060, while THAs are projected to total 1,982,099 by that time. Consequently, the mounting number of orthopedic procedures is a significant driver of the venous thromboembolism market's growth.

Leading companies within the venous thromboembolism market are spearheading the development of innovative anticoagulant drugs and solutions to maintain their market positions. Advances in anticoagulants hold the potential to yield more effective drugs capable of preventing or treating venous thromboembolism. For example, in September 2022, Anthos Therapeutics, a US-based clinical-stage biotherapeutics company, secured regulatory approval for its abelacimab anticoagulant medication from the Food and Drug Administration (FDA). This fully human monoclonal antibody is indicated for stroke and systemic embolism prevention in atrial fibrillation patients. The newly developed abelacimab, a once-monthly dual-acting antibody, is designed to provide hemostasis-sparing anticoagulation by inhibiting Factor XI.

In August 2022, Boston Scientific Corporation, a US-based leader in surface modification technologies, acquired Obsidio, Inc., a US-based company specializing in biodegradable embolic materials for treating venous conditions, for an undisclosed amount. This acquisition strengthens Boston Scientific's portfolio of innovative therapies, expanding its capabilities in minimally invasive procedures aimed at patients with venous conditions. The acquisition is expected to enhance the company's offerings in the growing field of venous health, particularly with Obsidio's cutting-edge materials designed to improve treatment outcomes for patients suffering from conditions like venous thromboembolism (VTE).

Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the venous thromboembolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The venous thromboembolism market consists of revenues earned by entities by providing services such as surgical assistance and thrombolytic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The venous thromboembolism market also includes the sales of heparin, apixaban, dabigatran, rivaroxaban, edoxaban and warfarin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Venous Thromboembolism Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on venous thromboembolism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for venous thromboembolism ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The venous thromboembolism market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Deep Vein Thrombosis; Pulmonary Embolism; Other Types
2) By Treatment: Anti-Clotting Medications; Mechanical Devices; Thrombolytic Therapy; Other Treatment
3) By End Users: Hospitals; Homecare; Specialty Centers; Other End Users
Subsegments:
1) By Deep Vein Thrombosis (DVT): Proximal DVT; Distal DVT; Asymptomatic DVT
2) By Pulmonary Embolism (PE): Acute PE; Chronic PE; Submassive PE
3) By Other Types: Thrombophlebitis; Superficial Vein Thrombosis; Post-Thrombotic Syndrome
Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; Merck and Co. Inc.; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r29225

1. Executive Summary

2. Venous Thromboembolism Market Characteristics

3. Venous Thromboembolism Market Trends And Strategies

4. Venous Thromboembolism Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Venous Thromboembolism Growth Analysis And Strategic Analysis Framework

5.1. Global Venous Thromboembolism PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Venous Thromboembolism Market Growth Rate Analysis
5.4. Global Venous Thromboembolism Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Venous Thromboembolism Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Venous Thromboembolism Total Addressable Market (TAM)

6. Venous Thromboembolism Market Segmentation

6.1. Global Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Deep Vein Thrombosis
Pulmonary Embolism
Other Types
6.2. Global Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-Clotting Medications
Mechanical Devices
Thrombolytic Therapy
Other Treatment
6.3. Global Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Centers
Other End Users
6.4. Global Venous Thromboembolism Market, Sub-Segmentation Of Deep Vein Thrombosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Proximal DVT
Distal DVT
Asymptomatic DVT
6.5. Global Venous Thromboembolism Market, Sub-Segmentation Of Pulmonary Embolism, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute PE
Chronic PE
Submassive PE
6.6. Global Venous Thromboembolism Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Thrombophlebitis
Superficial Vein Thrombosis
Post-Thrombotic Syndrome

7. Venous Thromboembolism Market Regional And Country Analysis

7.1. Global Venous Thromboembolism Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Venous Thromboembolism Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Venous Thromboembolism Market

8.1. Asia-Pacific Venous Thromboembolism Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Venous Thromboembolism Market

9.1. China Venous Thromboembolism Market Overview
9.2. China Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Venous Thromboembolism Market

10.1. India Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Venous Thromboembolism Market

11.1. Japan Venous Thromboembolism Market Overview
11.2. Japan Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Venous Thromboembolism Market

12.1. Australia Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Venous Thromboembolism Market

13.1. Indonesia Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Venous Thromboembolism Market

14.1. South Korea Venous Thromboembolism Market Overview
14.2. South Korea Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Venous Thromboembolism Market

15.1. Western Europe Venous Thromboembolism Market Overview
15.2. Western Europe Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Venous Thromboembolism Market

16.1. UK Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Venous Thromboembolism Market

17.1. Germany Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Venous Thromboembolism Market

18.1. France Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Venous Thromboembolism Market

19.1. Italy Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Venous Thromboembolism Market

20.1. Spain Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Venous Thromboembolism Market

21.1. Eastern Europe Venous Thromboembolism Market Overview
21.2. Eastern Europe Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Venous Thromboembolism Market

22.1. Russia Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Venous Thromboembolism Market

23.1. North America Venous Thromboembolism Market Overview
23.2. North America Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Venous Thromboembolism Market

24.1. USA Venous Thromboembolism Market Overview
24.2. USA Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Venous Thromboembolism Market

25.1. Canada Venous Thromboembolism Market Overview
25.2. Canada Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Venous Thromboembolism Market

26.1. South America Venous Thromboembolism Market Overview
26.2. South America Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Venous Thromboembolism Market

27.1. Brazil Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Venous Thromboembolism Market

28.1. Middle East Venous Thromboembolism Market Overview
28.2. Middle East Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Venous Thromboembolism Market

29.1. Africa Venous Thromboembolism Market Overview
29.2. Africa Venous Thromboembolism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Venous Thromboembolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Venous Thromboembolism Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Venous Thromboembolism Market Competitive Landscape And Company Profiles

30.1. Venous Thromboembolism Market Competitive Landscape
30.2. Venous Thromboembolism Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Venous Thromboembolism Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Sanofi-Aventis LLC.
31.3. Bristol-Myers Squibb Company
31.4. GlaxoSmithKline plc.
31.5. Eli Lilly and Co Ltd.
31.6. Boehringer Ingelheim International GmbH
31.7. Teva Pharmaceutical Industries Ltd.
31.8. Daiichi Sankyo Company Limited
31.9. Sun Pharmaceutical Industries Limited
31.10. Otsuka Pharmaceutical Co. Ltd.
31.11. Menarini Group
31.12. Ipsen S.A.
31.13. Dr. Reddy's Laboratories Ltd.
31.14. Apotex Inc.
31.15. Hikma Pharmaceuticals PLC

32. Global Venous Thromboembolism Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Venous Thromboembolism Market

34. Recent Developments In The Venous Thromboembolism Market

35. Venous Thromboembolism Market High Potential Countries, Segments and Strategies

35.1 Venous Thromboembolism Market In 2029 - Countries Offering Most New Opportunities
35.2 Venous Thromboembolism Market In 2029 - Segments Offering Most New Opportunities
35.3 Venous Thromboembolism Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer